Article
作者: Wang, Yu-tian ; Cui, Nai-Qian ; Wang, Yu-Tian ; Jiang, Nan ; Liu, Zi-ying ; Cheng, Ning-ning ; Cheng, Ning-Ning ; Liu, Guan-Qiao ; Tian, Liang-jie ; Huang, Kui-yuan ; Deng, Song-Yun ; Yang, Bing-sheng ; Huang, Kui-Yuan ; Xu, Dao-rong ; Xu, Dao-Rong ; Xu, Ya-fei ; Tian, Liang-Jie ; Li, Xiao-ran ; Qian, Ji-kun ; Liu, Guan-qiao ; Ma, Yuan ; Qian, Ji-Kun ; Liu, Zi-Ying ; Yu, Bin ; Li, Xiao-Ran ; Cui, Nai-qian ; Shen, Ke ; Xu, Ya-Fei ; Huang, Xuan ; Yang, Bing-Sheng ; Gu, Yuan ; Chai, Yu ; Deng, Song-yun
ObjectiveOsteoclast (OC) over-activation is an important cause of bone loss that is strongly correlated with inflammation. Although the CD163/TWEAK/Fn14 axis has been implicated in several inflammatory pathologies, its contributions to inflammatory bone loss remain poorly understood. This study aimed to evaluate the interaction of the CD163/TWEAK/Fn14 axis with OC in inflammatory bone loss.MethodsTo assess the role of CD163 in bone homeostasis, we characterized the bone phenotypes of CD163-deficient mice and their wild-type littermates. CD163 and TWEAK levels were evaluated in the bone marrow of mice with LPS-induced bone loss and individuals with rheumatoid arthritis (RA). Bone mass changes were assessed using uCT and histology following supplementation with recombinant mouse CD163 protein (rCD163) or blockade of TWEAK/Fn14 signaling in CD163-deficient mice and mice with LPS-induced bone loss. The impact of CD163/TWEAK on OC differentiation and bone resorption capacity was analyzed in vitro.ResultsCD163 deficiency caused decreased bone mass and increased OC abundance. Lower CD163 expression and higher TWEAK expression were observed in the bone marrow of mice with LPS-induced bone loss and individuals with RA. TWEAK, mainly derived from CD68+ macrophages, was responsible for bone loss, and supplementing rCD163 or blocking TWEAK/Fn14 signaling contributed to rescue bone loss. TWEAK/Fn14 synergistically promoted RANKL-dependent OC differentiation and bone resorption capability through downstream mitogen-activated protein kinases (MAPK) signaling, while the pro-osteoclastic effect of TWEAK was suppressed by CD163.ConclusionOur findings suggest that the CD163/TWEAK/Fn14 axis is a potential therapeutic target for inflammatory bone loss by regulating osteoclastogenesis.